文献速递肝病消化道肿瘤与早癌

肝脏干扰素调节因子8表达抑制肝细胞癌进展并增强抗程序性细胞死亡蛋白-1治疗反应

Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy.
PubMed 文献 · Hepatology · 2022-01-24

研究基于肝细胞癌数据库发现,IRF8在肝细胞癌中表达降低与患者不良预后相关,IRF8低表达患者中干扰素-γ和PD-1信号通路受抑。在免疫健全小鼠中过表达IRF8可增强抗肿瘤效应,腺相关病毒8介导的肝脏IRF8恢复可抑制肝细胞癌进展并增强抗PD-1治疗反应。

要点

  • IRF8在肝细胞癌中表达降低与不良预后相关。
  • IRF8低表达肝细胞癌中干扰素-γ和PD-1信号通路受抑。
  • 肝脏IRF8恢复抑制肝细胞癌进展并增强抗PD-1治疗反应。

核心结论

  • IRF8是肝细胞癌的重要预后生物标志物,可预测抗PD-1治疗的反应和敏感性,并作为增强免疫治疗疗效的治疗靶点。

研究设计与样本

  • 基于肝细胞癌数据库的Kaplan-Meier生存分析、基因集富集分析,以及免疫健全小鼠肿瘤模型实验。

主要发现

  • 在调节干扰素信号的九个IRF成员中,IRF8在肝细胞癌中表达降低与患者不良预后相关。
  • 基因集富集分析显示,IRF8低表达肝细胞癌患者中干扰素-γ和PD-1信号特征为最受抑制的通路。
  • 在免疫健全小鼠中过表达IRF8显著增强抗肿瘤效应,调节肿瘤相关巨噬细胞浸润和T细胞耗竭。
  • IRF8通过抑制趋化因子(C-C基序)配体20表达调控肿瘤相关巨噬细胞募集。
  • IRF8介导的c-fos转录抑制导致CCL20表达降低,而非直接结合CCL20启动子区域。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Therapeutic blockade of the programmed cell death protein-1 (PD-1) immune checkpoint pathways has resulted in significant reactivation of T cell-mediated antitumor immunity and is a promising clinical anticancer treatment modality in several tumor types, but the durable response rate remains relatively low (15%-20%) in most patients with HCC for unknown reasons. Evidence reveals that the interferon signaling pathway plays a critical role in modulating the efficacy and sensitivity of anti-PD-1 therapy against multiple tumor types, but the mechanisms are unclear. APPROACH AND RESULTS: Using Kaplan-Meier survival analysis based on HCC databases, we found that deceased expression of interferon regulatory factor (IRF) 8 in HCC, among all the nine IRF members that regulate interferon signals, was associated with poor prognosis of patients with HCC. Moreover, gene set enrichment analysis identified the interferon-gamma and PD-1 signaling signatures as the top suppressed pathways in patients with IRF8-low HCC. Contrarily, overexpression of IRF8 in HCC cells significantly enhanced antitumor effects in immune-competent mice, modulating infiltration of tumor-associated macrophages (TAMs) and T cell exhaustion in tumor microenvironment. We further demonstrated that IRF8 regulated recruitment of TAMs by inhibiting the expression of chemokine (C-C motif) ligand 20 (CCL20). Mechanically, IRF8-mediated repression of c-fos transcription resulted in decreased expression of CCL20, rather than directly bound to CCL20 promoter region. Importantly, adeno-associated virus 8-mediated hepatic IRF8 rescue significantly suppressed HCC progression and enhanced the response to anti-PD-1 therapy. CONCLUSIONS: This work identified IRF8 as an important prognostic biomarker in patients with HCC that predicted the response and sensitivity to anti-PD-1 therapy and uncovered it as a therapeutic target for enhancing the efficacy of immune therapy.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wu H, Li Y, Shi G, et al. Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy. Hepatology. 2022. PMID: 34989013. doi:10.1002/hep.32316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。